ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $8.50 Average PT from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $8.50.

Several research firms have recently weighed in on ALXO. Jefferies Financial Group downgraded ALX Oncology from a “buy” rating to a “hold” rating and cut their target price for the company from $12.00 to $2.00 in a research report on Thursday, December 19th. HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Wednesday, December 18th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th.

ALX Oncology Trading Down 4.1 %

Shares of NASDAQ ALXO opened at $1.62 on Monday. ALX Oncology has a 1-year low of $1.19 and a 1-year high of $17.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The business’s 50 day moving average is $1.52 and its two-hundred day moving average is $3.08. The stock has a market capitalization of $85.44 million, a P/E ratio of -0.54 and a beta of 1.04.

Insider Buying and Selling at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was bought at an average price of $1.55 per share, for a total transaction of $46,500.00. Following the acquisition, the director now directly owns 33,000 shares of the company’s stock, valued at $51,150. This represents a 1,000.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 33.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ALX Oncology

Institutional investors have recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the period. Hsbc Holdings PLC bought a new stake in ALX Oncology during the 2nd quarter valued at $63,000. AQR Capital Management LLC lifted its holdings in shares of ALX Oncology by 50.7% in the 2nd quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after buying an additional 6,080 shares during the period. SG Americas Securities LLC grew its position in shares of ALX Oncology by 33.6% during the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock worth $50,000 after buying an additional 6,888 shares in the last quarter. Finally, Algert Global LLC purchased a new position in shares of ALX Oncology during the second quarter valued at $249,000. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.